Selection of mouse models of cancer is often based simply on availability of a mouse strain and a known compatible tumor. Frequently this results in use of tumor models long on history but short on homology and quality control. Other factors including genetics, sex, immunological status, method and site of tumor implantation, technical competence, biological activity of the tumor, protocol sequence and timing, and selection of endpoints interact to produce outcomes in tumor models. Common reliance on survival and tumor burden data in a single mouse model often skews expectations towards high remission and cure rates; a finding seldom duplicated in clinical trials. Inherent limitations of tumor models coupled with the advent of new therapeutic targets reinforce need for careful attention to design, conduct, and stringent selection of in vivo and ex vivo endpoints. Preclinical efficacy testing for anti-tumor therapies should progress through a series of models of increasing sophistication that includes incorporation of genetically engineered animals, and orthotopic and combination therapy models. Pharmacology and safety testing in tumor-bearing animals may also help to improve predictive value of these models for clinical efficacy. Trends in bioinformatics, genetic refinements, and specialized imaging techniques are helping to maintain mice as the most scientifically and economically powerful model of malignant neoplasms.
Abate-Shen, C., and Shen, M.M. (2002). Mouse models of prostate carcinogenesis. Trends Genet18, S1—S5.
2.
Alvarez, E. (2002). B16 murine melanoma: historical perspective on the development of a solid tumor model. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
3.
An, Z., Jiang, P., Wang, X., Moossa, A.R., and Hoffman, R.M. (1999). Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis17, 265—70.
4.
Anderson, R.N. (2002). Deaths: leading causes for 2000. National Vital Statistics Report50, 12—4.
5.
Arias E., and Smith, B.L. (2003). Deaths: preliminary data for 2001. National Vital Statistics Report51, 1—16.
6.
Artandi, S.E. (2002). Telomore shortening and cell fates in mouse models of neoplasia. Trends Mol Med8, 44—7.
7.
Atassi, G., Dumont, P., Kabbe, H.J., and Yoder, O. (1988). A new antitumour agent, batracylin, selected by a preclinical solid tumour model. Drugs Exp Clin Res14, 571—4.
8.
Averbook, B., Schuh, J.C.L., Papay, R., and Maliszewski, C. (2002). Antitumor effects of flt3 ligand in transplanted murine tumor models. J Immunother25, 27—35.
9.
Balmain, A. (2002). Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell108, 145—52.
10.
Bankert, R.B., Egilmez, N.K., and Hess, S.D. (2001). Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol22, 386—93.
11.
Bankert, R.B., Hess, S.D., and Egilmez, N.K. (2002). SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci7, 44—62.
12.
Bardeesy, N., Sharpless, N.E., DePinho, R.A., and Merlino, G. (2001). The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model. Semin Cancer Biol11, 201—8.
13.
Begemann, M., Fuller, G.N., and Holland, E.C. (2002). Genetic modeling of glioma formation in mice. Brain Pathol12, 117—32.
14.
Beltinger, C., and Debatin, K.-M. (2001). Murine models for experimental therapy of pediatric solid tumors with poor prognosis. Int J Cancer92, 313—8.
15.
Bernardi, R., Grisendi, S., and Pandolfi, P.P. (2002). Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene21, 3445—58.
16.
Berr, S.S., Roche, J.K., El-Rifai, W., Smith Jr., M.F., and Powell, S.M. (2003). Magnetic resonance imaging of gastric cancer in Tff1 knock-out mice. Magn Reson Med49, 1033—6.
17.
Bloomston, M., Zervos, E.E., and Rosemurgy II, A.S. (2002). Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol9, 668—74.
18.
Bogden, A.E., Esber, H.J., Taylor, D.J., and Gray, J.H. (1974). Comparative study on the effects of surgery, chemotherapy, and immunotherapy, alone and in combination, on metastases of the 13762 mammary adenocarcinoma. Cancer Res34, 1627—31.
19.
Boivin, G.P., Washington, K., Yang, K., Ward, J.M., Pretlow, T.P., Russell, R., Besselsen, D.G., Godfrey, V.L., Doetschman, T., Dove, W.F., Pitot, H.C., Halberg, R.B., Itzkowitz, S.H., Groden, J., and Coffey, R.J. (2003). Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology124, 762—7.
20.
Bonfil, R.D., Russo, D.M., Binda, M.M., Delgado, F.M., and Vincenti, M. (2002). Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder . Urol Oncol7, 159—66.
21.
Boone, C.W., Steele, V.E., and Kelloff, G.J. (1992). Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res267, 251—5.
22.
Boyd, D.D., Kim, S.J., Wang, H., Jones, T.R., and Gallick, G.E. (2003). A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol162, 619.
23.
Burger, M.M. (2000). UICC study group on basic and clinical cancer research: animal models for the natural history of cancer. Int J Cancer85, 303—5.
24.
Burgos, J.S., Rosol, M., Moats, R.A., Khankaldyyan, V., Kohn, D.B., Nelson Jr., M.D., and Laug, W.E. (2003). Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. BioTechniques34, 1184—8.
25.
Cardiff, R.D. (2001). Validity of mouse mammary tumour models for human breast cancer: comparative pathology. Microsc Res Tech52, 224—30.
26.
Carson III, W.E., and Walker, M.J. (2002). Animal models of melanoma. Tumor Models in Cancer Research, Teicher B. AHumana Press , Totowa, NJ.
27.
Casas, A., Fukuda, H., Meiss, R., and Batlle, A.M. (1999). Topical and intratumoral photodynamic therapy with 5-aminolevulinic acid in a subcutaneous murine mammary adenocarcinoma . Cancer Lett141, 29—38.
28.
Castillo, R., Diaz, J.W., Veloso, A., and Gavilondo, J. (1982). Leukemoid reaction induced by different transplantable tumors in three inbred mouse strains. Neoplasma29, 73—9.
29.
Chakrabarty, A., Hillman, G.G., Maughan, R.L., Visscher, D.W., Ali, E., Pontes, J.E., and Haas, G.P. (1994). Influence of tumor site on the therapy of murine kidney cancer. Anticancer Res14, 373—8.
30.
Chen, J.J.W., Peck, K., Hong, T.-M., Yang, S.-C., Sher, Y.-P., Shih, J.-Y., Wu, R., Cheng, J.-L., Roffler, S.R., Wu, C.-W., and Yang, P.-C. (2001). Global analysis of gene expression in invasion by a lung cancer model. Cancer Res61, 5223—30.
31.
Clarke, R. (2002). Human breast-cancer xenografts as models of the human disease. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
32.
Corbett, T.H., Griswold Jr, D.P., Wolpert, M.K., Venditti , J.M., and Schabel Jr., F.M. (1979). Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rep63, 799—801.
33.
Corbett, T.H., Panchapor, C., Polin, L., Lowichik, N., Pugh, S., White, K., Kushner, J.Meyer, J., Czarnecki, J., Chinnukroh, S., Edelstein, M., LoRusso, P., Heilbrun, L., Horwitz, J.P., Grieshaber, C., Perni, R., Wentland, M., Coughlin, S., Elenbaas, S., Philion, R., and Rake, J. (1999). Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs17, 17—27.
34.
Corbett, T.H., Polin, L., Roberts, B.J., Lawson, A.J., Leopold , III W.R., White, K., Kushner , J., Paluch, J., Hazeldine, S., Moore, R., Rake, J., and Horwitz, J.P. (2002). Transplantable syngeneic rodent tumors: solid tumors in mice. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
35.
Couse, J.F., Davis, V.L., Hanson, R.B., Jefferson, W.N., McLachlan, J.A., Bullock, B.C., Newbold, R.R., and Korach, K.S. (1997). Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. Mol Carcinog19, 236—42.
36.
Culp, L.A., Holleran, J.L., and Miller, C.J. (2001). Tracking prostate carcinoma micrometastasis to multiple organs using histochemical marker genes and novel cell systems. Histol Histopathol16, 945—53.
37.
Dellian, M., Witwer, B.P., Salehi, H.A., Yuan F., and Jain, R.K. (1996). Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment . Am J Pathol149, 59—71.
38.
Dewhirst, M.W., Thrall, D., and MacEwen, E.G. (2002). Spontaneous pet animal cancers. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
39.
Diament, M.J., Garcia, C., Stillitani, I., Saavedra, V.M., Manzur, T., Vauthay, L., and Klein, S. (1998). Spontaneous murine lung adenocarcinoma (P07): a new experimental model to study paraneoplastic syndromes of lung cancer . Int J Mol Med2, 45—50.
40.
Drexler, H.G., Dirks, W.G., Matsuo, Y., and MacLeod, R.A. (2003). False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia17, 416—26.
41.
Dvorak, H.F., Harvey, V.S., Estrella, P., Brown, L.F., McDonagh, J., and Dvorak, A.M. (1987). Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest57, 673—86.
42.
Dykes, D.J., and Waud, W.R. (2002). Murine L1210 and P388 Leukemias. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
43.
Eccles, S.A. (2002). Models for evaluation of targeted therapies of metastatic disease. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
44.
Edinger, M., Sweeney, T.J., Tucker, A.A., Olomu, A.B., Negrin, R.S., and Contag, C.H. (1999). Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia1, 303—10.
45.
Eto, M., Harada, M., Tamada, K., Tokuda, N., Koikawa, Y., Nakamura, M., Nomoto, K., and Naito, S. (2000). Antitumor activity of interleukin-12 against murine bladder cancer. J Urol163, 1549—52.
46.
Fausto, N. (1999). Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis19, 243—52.
47.
Feitelson, M.A., and Larkin, J.D. (2001). New animal models of hepatitis B and C. ILAR J42, 127—38.
48.
Fogh, J., Fogh, J.M., and Orfeo, T. (1977). One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst59, 221—6.
49.
Fu, X., Guadagni, F., and Hoffman, R.M. (1992). A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens . Proc Natl Acad Sci USA89, 5645—9.
50.
Furukawa, T., Kubota, T., Watanabe, M., Kitajima, M., and Hoffman, R.M. (1993a). A novel “patient-like” treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res53, 3070—2.
51.
Furukawa, T., Kubota, T., Watanabe, M., Kuo, T.H., Kitajima, M., and Hoffman, R.M. (1993b). Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. Int J Cancer54, 397—401.
52.
Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., Leonhardt, H., and Jaenisch, R. (2003). Induction of tumors in mice by genomic hypomethylation . Science300, 489.
53.
Gershwin, M.E., Ikeda, R.M., Kawakami, T.G., and Owens, R.B. (1977). Immunobiology of heterotransplanted human tumors in nude mice. J Natl Cancer Inst58, 1455—60.
54.
Giard, D.J., Aaronson, S.A., Todaro, G.J., Arnstein, P., Kersey, J.H., Dosik, H., andParks, W.P. (1973). In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst51, 1417—23.
55.
Giovanella, B. (2002). Xenotransplantation of human cell cultures in nude mice. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
56.
Giraldi, T., Zorzet, S., Perissin, L., and Rapozzi, V. (2000). Stress and chemotherapy: combined effects on tumor progression and immunity in animal models. Ann NY Acad Sci917, 549—59.
57.
Goodman, J.I., and Watson, R.E. (2002). Altered DNA methylation: a secondary mechanism involved in carcinogenesis. Annu Rev Pharmacol Toxicol42, 501—25.
58.
Goytisolo, F.A., and Blasco, M.A. (2002). Many ways to telomere dysfunction: in vivo studies using mouse models. Oncogene21, 584—91.
59.
Granger, M.P., Wright, W.E., and Shay, J.W. (2002). Telomerase in cancer and aging. Crit Rev Oncol Hematol41, 29—40.
60.
Gunduz, N., Fisher, B., and Saffer, E.A. (1979). Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res39, 3861—5.
61.
Gutmann, D.H., Baker, S.J., Giovannini, M., Garbow, J., and Weiss, W. (2003). Mouse models of human cancer consortium symposium on nervous system tumors. Cancer Res63, 3001—4.
62.
Hann, B., and Balmain, A. (2001). Building `validated' mouse models of human cancer . Curr Opin Cell Biol13, 778—84.
63.
Harrison, S. (2002). Perspective on the history of tumor models. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
64.
Hay, R.J. (1991). Operator-induced contamination in cell culture systems. Dev Biol Stand75, 193—204.
65.
Herber, R., Liem, A., Pitot, H., and Lambert, P.F. (1996). Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol70, 1873—81.
66.
Herzig, M., and Christofori, G. (2002). Recent advances in cancer research: mouse models of tumorigenesis. Biochim Biophys Acta1602, 97—113.
67.
Heyer, J., Yang, K., Lipkin, M., Edelmann, W., and Kucherlapati, R. (1999). Mouse models for colorectal cancer. Oncogene18, 5325—33.
68.
Hillman, G.G. (2002). Experimental animal models for renal cell carcinoma. Tumor Models in Cancer Research, Teicher B. A. Humana Press , Totowa, NJ.
69.
Hoffman, R.M. (1999). Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs174, 343—59.
70.
Hoffman, R.M. (2002). Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Oncology3, 546—56.
Hoon, D.S., Fujimoto, A., Shu, S., and Taback, B. (2002). Assessment of genetic heterogeneity in tumors using laser capture microdissection. MethEnzymol356, 302—9.
73.
Horig, H., Wainstein, A., Long, L., Kahn, D., Soni, S., Marcus, A., Edelmann, Kucherlapati, W.R., and Kaufman, H.L. (2001). A new mouse model for evaluating the immunotherapy of human colorectal cancer. Cancer Res61, 8520.
74.
Hotz, H.G., Hines, O.J., Foitzik, T., and Reber, H.A. (2000). Animal models of exocrine pancreatic cancer. Int J Colorectal Dis15, 136—43.
75.
Houghton, P.J., Adamson, P.C., Blaney, S., Fine, H.A., Gorlick, R., Haber, M., Helman, L., Hirschfeld, S., Hollingshead, M.G., Israel, M.A., Lock, R.B., Maris, J.M., Merlino, G., Patterson, W., Reynolds, C.P., Shannon, K., Yu, A., Yu, J., and Smith, M.A. (2002). Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res8, 3646—57.
76.
Hursting, S.D. (1997). Experimental models of gene-environment interaction for cancer chemoprevention studies. Curr Opin Oncol9, 487—91.
77.
Huseby, R.A. (1969). Utility and failure of models in oncology. Fed Proc28, 211—5.
78.
Hutchinson, J.N., and Muller, W.J. (2000). Transgenic mouse models of human breast cancer . Oncogene19, 6130—7.
79.
Jackson-Grusby, L. (2002). Modeling cancer in mice. Oncogene21, 5504—14.
80.
Jain, R.K., Munn, J.J., and Fukumura, D. (2002). Transparent window models and intravital microscopy: imagine gene expression, physiological function, and drug delivery in tumors. Tumor Models in Cancer Research, Teicher B. A. Humana Press , Totowa, NJ.
81.
Jonkers, J., and Berns, A. (2002). Conditional mouse models of sporadic cancer. Nat Rev Cancer2, 251—65.
82.
Justice, M.J., Noveroske, J.K., Weber, J.S., Zheng, B., and Bradley, A. (1999). Mouse ENU mutagenesis. Hum Mol Genet8, 1955.
83.
Kennel, S.J., Lankford, T., Davern, S., Foote, L., Taniguchi, K., Ohizumi, I., Tsutsumi, Y., Nakagawa, S., Mayumi, T., and Mirzadeh, S. (2002). Therapy of rat tracheal carcinoma IC-12 in SCID mice: vascular targeting with [213Bi]-MAb TES-23. Eur J Cancer38, 1278—87.
84.
Kerbel, R.S. (1999). What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev17, 301—4.
85.
Keshavarzi, A., Vaezy, S., Noble, M.L., Chi, E.Y., Walker, C., Martin, R.W., and Fujimoto, V.Y. (2002). Treatment of uterine leiomyosarcoma in a xenograft nude mouse model using high-intensity focused ultrasound: a potential treatment modality for recurrent pelvic disease. Gynecol Oncol86, 344—50.
86.
Killion, J.J., Radinsky, R., and Fidler, I.J. (1999). Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev17, 284.
87.
Klatt, P., and Serrano, M. (2003). Engineering cancer resistance in mice. Carcinogenesis24, 817.
88.
Klausner, R.D. (1999). Studying cancer in the mouse. Oncogene18, 5249—52.
89.
Knapp, D.W., and Waters, D.J. (1997). Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today3, 8—11.
90.
Kobaek-Larsen, M., Thorup, I., Diederichsen, A., Fenger, C., and Hoitinga, M.R. (2000). Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. Comp Med50, 16—26.
91.
Koike, K. (2002). Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. J Gastroenterol37, 55—64.
92.
Kristjansen, P.E.G. (2002). Tissue-isolated tumors in mice: ex vivo perfusion of human tumor xenografts. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
93.
Kruger, A., Schirrmacher, V., and Khokha, R. (1999). The bacterial lacZ gene: an important tool for metastasis research and evaluation of new cancer therapies. Cancer Metastasis Rev17, 285—94.
94.
Kunstfeld, R., Wickenhauser, G., Michaelis, U., Teifel, M., Umek, W., Naujoks, K., Wolff, K., and Petzelbauer, P. (2003). Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a ”humanized” SCID mouse model. J Invest Dermatol120, 476—82.
95.
Kuo, T.-H., Kubota, T., Watanabe, M., Furukawa, T., Kase, S., Tanino, H., Saikawa, Y., Ishibiki, K., Kitajima, M., and Hoffman, R.M. (1993). Sitespecific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data . Anticancer Res13, 627—30.
96.
Lapidot, T., Fajerman, Y., and Kollet, O. (1997). Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis . J Mol Med75, 664—73.
97.
Laster Jr., W.R., Schabel Jr, F.M., Skipper, H.E., Wilcox, W.S., and Thomson, J.R. (1961). Experimental evaluation of potential anticancer agents IV. host weight loss as it relates to false positives in drug evaluation. Cancer Res21, 895—906.
98.
Li, C.Y., Shan, S., Huang, Q., Braun, R.D., Lanzen, J., Hu, K., Lin, P., and Dewhirst, M.W. (2000). Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst92, 143—7.
99.
Liebelt, R.A., Gehring, G., Delmonte, L., Schuster, G., and Liebelt, A.G. (1974). Paraneoplastic syndromes in experimental animal model systems. Ann NY Acad Sci230, 547—64.
100.
Lin, J., Sahakian, D.C., de Morais, S.M., Xu, J.J., Polzer, R.J., and Winter, S.M. (2003). The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem3, 1125—4.
101.
Liu, J., and Johnston, M.R. (2002). Animal models for studying lung cancer and evaluating novel intervention strategies. Surg Oncol11, 217—27.
102.
Maierhofer, C., Gangnus, R., Diebold, J., and Speicher, M.R. (2003). Multicolor deconvolution microscopy of thick biological specimens. Am J Pathol162, 373.
103.
Malkinson, A.M. (2001). Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer32, 265—79.
104.
Manivasager, V., Heng, P.W., Hao, J., Zheng, W., Soo, K.C., and Olivo, M. (2002). Macro-microscopic fluorescence imaging of human NPC xenografts in a murine model using topical vs intravenous administration of 5-aminolevulinic acid. Int J Oncol21, 1003—7.
105.
Manzotti, C., Audisio, R.A., and Pratesi, G. (1993). Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis11, 5—14.
106.
McClatchey A.I. (1999). Modeling metastasis in the mouse. Oncogene18, 5334—9.
107.
Menon, K., and Teicher, B.A. (2002). Metastasis models: lungs, spleen/liver, bone, and brain. Tumor Models in Cancer Research, Teicher B. A. Humana Press, Totowa, NJ.
108.
Meuwissen, R., Jonkers J., and Berns, A. (2001). Mouse models for sporadic cancer. Exp Cell Res264, 100—10.
109.
Mickisch, G.H., Merlino, G.T., Galski, H., Gottesman, M.M., and Pastan, I. (1991). Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA88, 547—51.
110.
Monsky, W.L., Carreira, C.M., Tsuzuki, Y., Gohongi, T., Fukumura, D., and Jain, R.K. (2002). Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res8, 1008—13.
111.
Moore, K.J., and Nagle, D.L. (2000). Complex trait analysis in the mouse: the strengths, the limitations and the promise yet to come. Annu Rev Genet34, 653—86.
112.
Moseley, G.W., Elliott, J., Wright, M.D., Partridge, L.J., and Monk, P.N. (2003). Interspecies contamination of the KM3 cell line: implications for CD63 function in melanoma metastasis. Int J Cancer105, 613—6.
113.
Mukherjee, P., El-Abbadi, M.M., Kasperzyk, J.L., Ranes, M.K., and Seyfried, T.N. (2002). Dietary restriction reduced angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer86, 1615—21.
114.
Myers, J.N., Holsinger, F.C., Jasser, S.A., Bekele, B.N., and Fidler, I.J. (2002). An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res8, 293—8.
115.
Naf, D., Krupke, D.M., Sundberg, J.P., Eppig, J.T., and Bult, C.J. (2002). The mouse tumor biology database: a public resource for cancer genetics and pathology of the mouse. Cancer Res62, 1235.
116.
Naito, S., Giavazzi, R., Walker, S.M., Itoh, K., Mayo, J., and Fidler, I.J. (1987a). Growth and metastatic behavior of human tumor cells implanted into nude and beige nude mice. Clin Exp Metastasis5, 135—46.
117.
Naito, S., von Eschenback, A.C., and Fidler, I.J. (1987b). Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice . J Natl Cancer Inst78, 377—85.
118.
Navone, N.M., Logothetis, C.J., von Eschenbach, A.C., and Troncoso, P. (1999). Model systems of prostate cancer: uses and limitations . Cancer Metastasis Rev17, 361—71.
119.
Nelson, A.L., Algon, S.A., Munasinghe, J., Graves, O., Goumnerova, L., Burstein, D., Pomeroy, S.L., and Kim, J.Y. (2003). Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol62, 259—67.
120.
Nicklas, W., Kraft, V., and Meyer, B. (1993). Contamination of transplantable tumors, cell lines, and monoclonal antibodies with rodent viruses. Lab Anim Sci43, 296—300.
121.
Nyska, A., Dayan, A., and Maronpot, R.R. (2002). New tools in therapeutic research—prostatic cancer and models. Toxicol Pathol30, 283—7.
122.
Opitz, O.G., Harada, H., Suliman, Y., Rhoades, B., Sharpless, N.E., Kent, R., Kopelovich, L., Nakagawa, H., and Rustgi, A.K. (2002). A mouse model of human oral-esophageal cancer . J Clin Invest110, 761.
123.
Orsulic, S., Li, Y., Soslow, R.A., Vitale-Cross, L.A., Gutkind, J.S., and Varmus, H.E. (2002). Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell1, 53—62.
Pettaway, C.A., Pathak, S., Greene, G., Ramirez, E., Wilson, M.R., Killion, J.J., and Fidler, I.J. (1996). Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic inplantation in nude mice. Clin Cancer Res2, 1627—36.
Rahman, N.A., and Huhtaniemi, I.T. (2001). Ovarian tumorigenesis in mice transgenic for murine inhibin alpha subunit promoter-driven Simian Virus 40 T-antigen ontogeny, functional characteristics, and endocrine effects . Biol Reprod64, 1122—30.
128.
Rahman, N.A., Kananen Rilianawati, K., Paukku, T., Mikola, M., Markkula, M., Hamalainen, T., and Huhtaniemi, I.T. (1998). Transgenic mouse models for gonadal tumorigenesis. Mol Cell Endocrinol145, 167—74.
129.
Ray, P., Wu, A.M., and Gambhir, S.S. (2003). Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res63, 1160—5.
130.
Reilly, K.M., and Jacks, T. (2001). Genetically engineered mouse models of astrocytoma: GEMs in the rough? Semin Cancer Biol11, 177—91.
131.
Resor, L., Bowen, T.J., and Wynshaw-Boris, A. (2001). Unraveling human cancer in the mouse: recent refinements to modeling and analysis. Hum Mol Genet10, 669—75.
132.
Rew, D.A. (2000a). Modelling in tumour biology part I: modelling concepts and structures. Eur J Surg Oncol26, 78—94.
133.
Rew, D.A. (2000b). Modelling in tumour biology part II: modelling cancer therapy. Eur J Surg Oncol26, 181—8.
134.
Rideout III, W.M., Wakayama, T., Wutz , A., Eggan, K., Jackson-Grusby , L., Dausman, J., Yanagimachi, R., and Jaenisch, R. (2000). Generation of mice from wild-type and targeted ES cells by nuclear cloning . Nat Genet24, 109—10.
135.
Righi, L., Deaglio, S., Pecchioni, C., Gregorini, A., Horenstein, A.L., Bussolati, G., Sapino, A., and Malavasi, F. (2003). Role of CD31/platelet endothelial cell adhesion molecule-1 expression in in vitro and in vivo growth and differentiation of human breast cancer cells. Am J Pathol162, 1163.
136.
Rosenberg, E., Holmes, M., Tenenholz, T., Khalil, A.E.R., and Valerie, K. (2003). Preservation of fluorescent protein activity in tumor tissue. BioTechniques34, 476—80.
137.
Rosenberg, M.P., and Bortner, D. (1999). Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metastasis Rev17, 295—9.
138.
Rosner, A., Miyoshi, K., Landesman-Bollag, E., Xu, X., Seldin, D.C., Moser, A.R., MacLeod, C.L., Shyamala, G., Gillgrass, A.E., and Cardiff, R.D. (2002). Pathway pathology: histological differences between ErbB/Ras and wnt pathway transgenic mammary tumors. Am J Pathol161, 1087.
139.
Royal, R., Lange, P.H., and Vessella, R. (1996). Preclinical models of prostate cancer. Semin Oncol23, 35—40.
140.
Ruggero, D., Grisendi, S., Piazza, F., Rego, E., Mari, F., Rao, P.H., Cordon-Cardo, C., and Pandolfi, P.P. (2003). Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science299, 259.
141.
Sadar, M.D., Akopian, V.A., and Beraldi, E. (2002). Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence . Mol Cancer Ther1, 629—37.
142.
Schipper, H., Goh, C.R., and Wang, T.L. (1995). Shifting the cancer paradigm: must we kill to cure?J Clin Oncol801—7.
143.
Schwartz, J., and Gu, X. (2002). Hamster oral cancer model. Tumor Models in Cancer Research, Teicher B. A., Humana Press, Totowa, NJ.
144.
Seki, N., Hayakawa, Y., Brooks, A.D., Wine, J., Wiltrout, R.H., Yagita, H., Tanner, J.E., Smyth M.J., and Sayers, T.J. (2003). Tumor necrosis factor-related apoptosis-inducing ligant-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res63, 207—13.
145.
Sharma, P., and Schreiber-Agus, N. (1999). Mouse models of prostate cancer. Oncogene18, 5349—55.
146.
Siemann, D.W. (1987). Satisfactory and unsatisfactory tumor models factors influencing the selection of a tumor model for experimental evaluation. Rodent Tumor Models in Experimental Cancer Therapy, Kallman, R. F., Pergamon Books, Inc, Elmsford, NY.
147.
Skipper, H.E. (1968). Biochemical, biological, pharmacologic, toxicologic, kinetic, and clinical (subhuman and human) relationships. Cancer21, 600— 10.
148.
Skipper, H.E. (1990). Tumor differences, drug differences, treatment design differences, and effects on therapeutic outcome (degree and duration of therapeutic response). Prog Clin Biol Res354, 81—98.
149.
Spitsbergen, J.M., and Kent, M.L. (2003). The state of the art of the zebrafish model for toxicology and toxicologic pathology research—advantages and current limitations. Toxicol Pathol31, 62—87.
150.
Standop, J., Schneider, M.B., Ulrich, A., and Pour, P.M. (2001). Experimental animal models in pancreatic carcinogenesis: lessons for human pancreatic cancer. Dig Dis19, 24—31.
151.
Steel, G.G. (1987). How well do xenografts maintain the therapeutic response characteristics of the source tumor in the donor patient? Rodent Tumor Models in Experimental Cancer Therapy, Kallman, R. F., Pergamon Books, Inc, Elmsford, NY.
152.
Strandberg, J.D. (2000). Comparative pathology of benign prostatic hyperplasia. Prostatic Diseases, Lepor, H. WB Saunders Co., Philadelphia, PA.
153.
Suttie, A., Nyska, A., Haseman, J.K., Moser, G.J., Hackett, T.R., and Goldsworthy, T.L. (2003). A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model . Toxicol Pathol31, 31—38.
154.
Tanaka, R., Okada, M., Kajimura, N., Otsubo, K., Gyotoku, M., Nagasaki, K., Ekimoto, H., and Yamaguchi, K. (1996). Triple paraneoplastic syndrome of hypercalcemia, leukocytosis and cachexia in two human tumor xenografts in nude mice. Jpn J Clin Oncol26, 88—94.
155.
Teicher, B.A. (1997). Models for minimal residual tumor. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Teicher, B. AHumana Press Inc., Totowa, NJ.
156.
Teicher, B.A. (2002). In vivo tumor response end points. Tumor Models in Cancer Research. Teicher, B. A. Humana Press, Totowa, NJ.
157.
Thompson, H.J., and Sporn, M.B. (2002). Mammary cancer in rats. Tumor Models in Cancer Research, Teicher, B. A., Humana Press, Totowa, NJ.
158.
Trainer, D.L., Kline, T., McCabe, F.L., Faucette, L.F., Feild, J., Chaikin, M., Anzano, M., Rieman, D., Hoffstein, S., Li, D.-J., Gennaro, D., Buscarino, C., Lynch, M., Poste, G., and Greig, R. (1988). Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer41, 287—96.
159.
Tuveson, D.A., and Jacks, T. (1999). Modeling human lung cancer in mice: similarities and shortcomings. Oncogene18, 5318—24.
160.
Tuveson, D.A., and Jacks, T. (2002). Technologically advanced cancermodeling in mice . Curr Opin Genet Dev12, 105—10.
161.
Uckun, F.M., and Sensel, M.G. (2002). SCID mouse models of human leukemia and lymphoma as tools for new agent development. Tumor Models in Cancer Research, Teicher B. A., Humana Press, Totowa, NJ .
162.
UKCCCR(1998). United kingdom coordinating committee on cancer research (UKCCCR) guidelines forthe welfare of animals in experimental neoplasia (second edition). Br J Cancer77, 1—10.
163.
Vail, D.M., and MacEwen, E.G. (1997). Spontaneously occurring tumors in companion animals as models for drug development. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Teicher, B. A., Humana Press, Totowa, NJ.
164.
van Dyke, T., and Jacks, T. (2002). Cancer modeling in the modern era: progress and challenges. Cell108, 135—44.
165.
Vanchieri, C. (2001). Move over, mouse: make way for the woodchucks, ferrets, and zebrafish. J Natl Cancer Inst93, 418—9.
166.
Vanderkerken, K., De Leenheer, E., Shipman, C., Asosingh, K., Willems, A., van Camp, B., and Croucher, P. (2003). Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res63, 287—9.
167.
Wallace, J. (2000). Humane endpoints and cancer research. ILAR J41, 87—93.
168.
Waters, D.J., and Bostwick, D.G. (1997). The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res17, 1467—70.
169.
Waters, D.J., Bostwick, D.G., and Murphy, G.P. (1998). Conference summary: first international workshop on animal models of prostate cancer. Prostate36, 47—48.
170.
Watson, A., Wu, X., and Bruchez, M. (2003). Lighting up cells with quantum dots. BioTechniques34, 296—303.
171.
Wetterwald, A., van der Pluijm, G., Que, I., Sijmons, B., Buijs, J., Karperien, M., Lowik, C.W.G.M., Gautschi, E., Thalmann, G.N., and Cecchini, M.G. (2002). Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol160, 1143.
172.
Wheeler, D.L., Church, D.M., Federhen, S., Lash, A.E., Madden, T.L., Pontius, J.U., Schuler, G.D., Schriml, L.M., Sequeira, E., Tatusova, T.A., and Wagner, L. (2003). Database resources of the national center for biotechnology. Nucleic Acids Res31, 28—33.
173.
Wichmann, M.W., Muller, C., Meyer, G., Adam, M., Angele, M.K., Eisenmenger S.J., and Schildberg, F.W. (2003). Different immune responses to abdominal surgery in men and women. Langenbeck's Arch Surg387, 397—401.
174.
Wilmanns, C., Fan, D., O'Brian, C.A., Bucana, C.D., and Fidler, I.J. (1992). Orthotopic and ectopic organ environments differently influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer52, 78—104.
175.
Yang, H., Berger, F., Tran, C., Gambhir, S.S., and Sawyers, C.L. (2003). MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. Prostate55, 39—47.
176.
Yoneda, T., Aufdemorte, T.B., Nishimura, R., Nishikawa, N., Sakuda, M., Alsina, M.M., Chavez, J.B., and Mundy, G.R. (1991). Occurrence of hypercalcemia and leukocytosis with cachexia in a human squamous cell carcinoma of the maxilla in athymic nude mice: a novel experimental model of three concomitant paraneoplastic syndromes . J Clin Oncol9, 468—77.
177.
Zan, Y., Haag, J.D., Chen, K.S., Shepel, L.A., Wigington, D., Wang, Y.R., Hu, R., Lopez-Guajardo, C.C., Brose, H.L., Porter, K.I., Leonard, R.A., Hitt, A.A., Schommer, S.L., Elegbede, A.F., and Gould, M.N. (2003). Production of knockout rats using ENU mutagenesis and a yeast-based screening assay. Nat Biotechnol21, 645—51.
178.
Zhang, Z., Yin, L., Zhang, Y., and Zhao, F. (2002). In situ transduction of cytosine deaminase gene followed by systemic use of 5-fluorocytosine inhibits tumor growth and metastasis in orthotopic prostate cancer mouse models. Chin Med J115, 227—31.
